The nation of Zimbabwe has declined a substantial US healthcare agreement valued at $367m (£272m) over five years over Washington's request for confidential biological samples.
This move was revealed following a internal memorandum from December was disclosed, which showed President Emmerson Mnangagwa believed the deal was "lopsided".
A government spokesperson later explained that the United States was demanding access to genetic material for scientific study and profit but refused to guarantee the resulting advantages from future vaccines.
"We are forced to start the difficult and regrettable task of winding down our support in Zimbabwe," said US ambassador to Zimbabwe Pamela Tremont in a statement.
Her embassy said the US had donated over $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has called for further negotiations to find a deal suitable to both sides so the nation's vital HIV treatment initiative can be sustained.
Wider Background
This rejection comes after a similar case in Kenya, where a high court blocked a similar health funding agreement after legal challenges were filed about the security of citizens' health data.
Since resuming office recently, US President Donald Trump has slashed foreign aid and closed the key foreign aid agency.
USAID had managed assistance for the American government, but Trump argued its spending was "inefficient" and his government was pursuing government-to-government deals to boost transparency and accountability.
According to reports, 16 African countries have so far agreed to similar health pacts, representing more than $18.3bn in new funding.
Details of the Rejected Deal
The funds for Zimbabwe was intended to supported "tackling HIV/Aids, TB, malaria, maternal and child health, and disease outbreak preparedness.
"We are confident this collaboration would have delivered immense advantages for Zimbabwean communities, especially the 1.2 million presently on antiretroviral therapy through American-funded programmes," Tremont commented.
However, government spokesperson Nick Mangwana said the arrangement was "unequal".
"The proposal required Zimbabwe to share its biological resources and data over an extended period, without any equivalent promise of access to any scientific breakthroughs – such as new medicines or tests – that might result from that provided information," his statement read.
"Put simply, our nation would provide the raw materials for scientific discovery without any certainty that the resulting innovations would be accessible to our citizens if a future health crisis emerge."
Sovereignty and International Frameworks
He also pointed out that the US's withdrawal from the global health body and its push of one-on-one deals were undermining frameworks already established via the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing framework designed to manage potential pandemics.
"This system is intended to ensure that when a country contributes its information, the resulting advantages – including vaccines and treatments – are shared equitably, not monopolised exclusively by those with the funds to create them."
The government's concerns over the US deal "should not be misconstrued as hostility towards the US," Mangwana stressed.
"We are open to further discussions with our US partners on how future co-operation could be arranged in a way that honours the independence and dignity of both nations."
Health Experts Reaction
The Zimbabwe College of Public Health Physicians (ZCPHP) said it recognised the official position, but urged that negotiations should continue given that a large portion of the nation's Aids initiatives were funded by foreign aid.
"Where specific concerns exist, including those relating to data governance or agreement terms, these can often be resolved via detailed discussion and mutually agreed protections," it said.
This impasse underscores the continuing debate between receiving vital foreign assistance and safeguarding a country's data in an increasingly data-driven world.